Regeneron (REGN) is a publicly traded Healthcare sector company. As of May 20, 2026, REGN trades at $643.47 with a market cap of $66.02B and a P/E ratio of 15.17. REGN moved +2.94% today. Year to date, REGN is -14.87%; over the trailing twelve months it is +5.69%. Its 52-week range spans $476.49 to $1,070.00. Analyst consensus is strong buy with an average price target of $884.89. Rallies surfaces REGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
REGN financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. REGN recently traded at $643.47. Market cap is $66.02B. P/E ratio is 15.17. Revenue is $14.92B.
| Metric | Value |
|---|---|
| Price | $643.47 |
| Market Cap | $66.02B |
| P/E Ratio | 15.17 |
| EPS | $42.56 |
| Dividend Yield | 0.94% |
| 52-Week High | $1,070.00 |
| 52-Week Low | $476.49 |
| Volume | 866.13K |
| Avg Volume | 0 |
| Revenue (TTM) | $14.92B |
| Net Income | $4.42B |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $14.34B | $4.50B | $43.07 |
| 2024 | $14.20B | $4.41B | $40.90 |
| 2023 | $13.12B | $3.95B | $37.05 |
| 2022 | $12.17B | $4.34B | $40.51 |
19 analysts cover REGN: 0 strong buy, 15 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $884.89.